Dr Richard T. Bryan MBChB PhD MRCS FAcadTM

Dr Richard T. Bryan

Institute of Cancer and Genomic Sciences
Director of Bladder Cancer Research Centre
Senior Research Fellow

Contact details

Institute of Cancer and Genomic Sciences
Robert Aitken Institute for Clinical Research
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Rik Bryan is a former clinical urologist, and now a full-time bladder cancer research academic. He is the Chief Investigator of the Bladder Cancer Prognosis Programme (BCPP), the SELENIB clinical trial, and POUT-T. He is the Director of the Bladder Cancer Research Centre (BCRC) in the Institute of Cancer & Genomic Sciences. The BCRC has a particular interest in the proteomics, genomics and epigenomics of bladder cancer and related biomarkers, and novel agents, technologies and pathways.



  • Fellow of the Academy of Translational Medicine 2016
  • PhD in Medicine 2007
  • Membership of The Royal College of Surgeons of England 1999
  • MBChB 1995


Rik Bryan qualified in Medicine at the University of Birmingham and subsequently entered surgical training. After completing a PhD in bladder cancer biology he became a higher surgical trainee in Urology. After 4-years as a Specialist Registrar, Rik left clinical urology to assist with the set-up of the Bladder Cancer Prognosis Programme (BCPP) in the Department of Public Health, Epidemiology and Biostatistics at the University of Birmingham, and was then subsequently appointed as a Senior Research Fellow in the School of Cancer Sciences. Rik is now the Chief Investigator of BCPP, which incorporates the SELENIB clinical trial.

Rik has an interest in all aspects of bladder cancer research and directs the Bladder Cancer Research Centre (BCRC) with a focus on translation. The particular interests of the BCRC include cancer proteomics/genomics/epigenomics, urinary biomarkers, novel therapeutics/technologies/devices, and clinical and epidemiological research. Rik has a track record of publication in all of these areas.

The BCRC also has an interest in upper tract urothelial cancer, and Rik is the Chief Investigator of POUT-T, the translational study linked to the POUT trial.

Postgraduate supervision

  • Intercalated BMedSci
  • MRes
  • PhD


  • Genomics and epigenomics, and associated biomarkers for non-invasive diagnosis and prognostication
  • Novel genomic platforms and approaches
  • Proteomics and urinary protein biomarkers
  • Novel therapeutics, technologies and devices and associated clinical trials
  • Tumour immunology and BCG mechanisms of action
  • Clinical, epidemiological and health economic research.

Aside from the research carried out at the University of Birmingham, the Bladder Cancer Group also has a number of important national and international collaborations with other bladder cancer investigators, including Professor Maurice Zeegers (Maastricht), Professor John Kelly (UCL), Professor Bart Kiemeney (Radboud), Professor Chris Probert (Liverpool), Dr Anne Kiltie (Oxford) and Professor Chas Bountra (Oxford).

Other activities

Aside from his bladder cancer research at the University of Birmingham, Rik also fulfils a number of other roles:

  • Member of the University of Birmingham’s Clinical Trials Oversight Committee (CTOC)
  • Member of the Bladder GeCIP, 100,000 Genomes Project
  • Trustee of the charity Action Bladder Cancer UK
  • Member of the T2 and Below Subgroup (TABS) of the NCRI Bladder & Renal Clinical Studies Group
  • Council Member and current Honorary Secretary of The Royal Society of Medicine Section of Urology
  • Member of the Trial Management Group of the Peri-Operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer (POUT) trial
  • Member of the Trial Management Group of the Clinical Research Office of the Endourology Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection (TURBT) versus conventional white light-assisted TURBT in primary non-muscle-invasive bladder cancer patients.


Recent publications


Bryan, R, Liu, W, Pirrie, S, Amir, R, Gallagher, J, Hughes, A, Jefferson, K, Knight, A, Nanton, V, Mintz, H, Pope, A, Catto, J, Patel, P & James, N 2021, 'Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath study', European urology. https://doi.org/10.1016/j.eururo.2021.02.021

Dowell, A, Munford, H, Goel, A, Gordon, N, James, N, Cheng, KK, Zeegers, M, Ward, D & Bryan, R 2021, 'PD-L2 is constitutively expressed in normal and malignant urothelium', Frontiers in Oncology.

Kibaru, J, Kotecha, P, Iya, AM, Russell, B, Abdullahi, M, Alhassan, SU, Mustapha, MI, Bryan, R & Van Hemelrijck, M 2021, 'Scoping Review protocol: Bladder cancer in Nigeria - what are the gaps in clinical care and research?', BMJ open, vol. 2021, no. 11, e041894. https://doi.org/10.1136/bmjopen-2020-041894

Russell, B, Haggstrom, C, Holmberg, L, Liedberg, F, Gårdmark, T, Bryan, R, Kumar, P & Van Hemelrijck, M 2021, 'Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators', BJUI Compass. https://doi.org/10.1002/bco2.65

Bessa, A, Rammant, E, Enting, D, Bryan, R, Khan, MS, Malde, S, Nair, R, Thurairaja, R, Cahill, F, Amery, S, Smith, S, Ahmed, K, Russell, B, Moss, C, Chatterton, K, Haggstrom, C & Van Hemelrijck, M 2021, 'The need for supportive mental wellbeing interventions in bladder cancer patients: a systematic review of the literature', PLoS ONE, vol. 16, no. 1, e0243136. https://doi.org/10.1371/journal.pone.0243136

Birtle, A, Johnson, M, Chester, J, Jones, R, Dolling, D, Bryan, R, Harris, C, WInterbottom, A, Blacker, A, Catto, J, Chakraborti, P, Donovan, J, Elliott, P, French, A, Jagdev, S, Jenkins, B, Keeley, F, Kockelbergh, R, Powles, T, Wagstaff, J, Wilson, C, Todd, R, Lewis, R & Hall, E 2020, 'Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial', The Lancet, vol. 395, no. 10232, pp. 1268-1277. https://doi.org/10.1016/S0140-6736(20)30415-3

Goel, A, Ward, D, Gordon, N, Abbotts, B, Zeegers, M, Cheng, KK, James, N, Bryan, R & Arnold, R 2020, 'Back-splicing transcript isoforms (circular RNAs) affect biologically relevant pathways and offer an additional layer of information to stratify NMIBC patients', Frontiers in Oncology, vol. 10, 812. https://doi.org/10.3389/fonc.2020.00812

Mintz, H, Dosanjh, A, Parsons, H, Hughes, A, Jakeman, A, Pope, A, Bryan, R, James, N & Patel, P 2020, 'Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial', Pilot and Feasibility Studies, vol. 6, 165. https://doi.org/10.1186/s40814-020-00713-y

Jochems, S, Reulen, R, Van Osch, F, Witlox, WJA, Goossens, ME, Brinkman, M, Giles, GG, Milne, RL, van den Brandt, PA, White, E, Weiderpass, E, Huybrechts, I, Hémon, B, Agudo, A, Bueno-de-Mesquita, B, Cheng, KK, van Schooten, FJ, Bryan, R, Wesselius, A & Zeegers, M 2020, 'Fruit consumption and the risk of bladder cancer: a pooled analysis by the BLadder cancer Epidemiology and Nutritional Determinants study', International Journal of Cancer. https://doi.org/10.1002/ijc.33008

Lipunova, N, Wesselius, A, Cheng, KK, van Schooten, F-J, Bryan, RT, Cazier, J-B & Zeegers, MP 2020, 'Gene-environment interaction with smoking for increased non-muscle-invasive bladder cancer tumor size', Translational Andrology and Urology, vol. 9, no. 3, pp. 1329-1337. https://doi.org/10.21037/tau-19-523

Kourbanhoussen, K, McMartin, C, Lodde, M, Zlotta, A, Bryan, R & Toren, P 2020, 'Switching cancers: a systematic review assessing the role for androgen suppressive therapy in bladder cancer', European Urology Focus. https://doi.org/10.1016/j.euf.2020.10.002

Bryan, RT & POUT Trial Management Group 2020, 'The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial', Trials, vol. 21, no. 1, 629. https://doi.org/10.1186/s13063-020-04559-w


Ward, DG, Arnold, R & Bryan, RT 2020, 'Molecular subtypes of T1 bladder cancer: biomolecular characteristics versus clinical utility', European urology, vol. 78, no. 4, pp. 538-539. https://doi.org/10.1016/j.eururo.2020.07.021


Spencer-Bowdage, S, Russell, B, Rigby, J, O'Kelly, J, Kelly, P, Page, M, Raw, C, Allchorne, P, Harper, P, Crew, J, Kockelbergh, R, Knight, A, Van Hemelrijck, M & Bryan, R 2021, 'The experience of UK bladder cancer patients during the COVID-19 pandemic: a survey-based snapshot', BJU International , vol. 127, no. 2, pp. 179-181. https://doi.org/10.1111/bju.15287

Other contribution

Lipunova, N, Bryan, RT & Zeegers, MP 2020, Bilirubin is not associated with urinary bladder cancer risk and prognosis: A Mendelian Randomization Study in the UK Biobank.. https://doi.org/10.1101/2020.08.13.20174102

View all publications in research portal


Bladder Cancer